We’ve also begun drug discovery efforts of our own,’ Anthropic says, as it buys Mithril and reports Claude results from six ...
Astra Zeneca and CSL have publicly endorsed Clever Culture's APAS agar plate reading tech – or at least they have come close ...
Tech Times on MSN
Patient dies in BMS multiple sclerosis CAR T trial; company cannot link death to drug
CAR T therapy multiple sclerosis trial death: Bristol Myers Squibb disclosed the first fatality in its Phase 1 Breakfree-2 ...
BioNTech SE and Bristol Myers Squibb Company reported initial results from the global Phase 2 ROSETTA Lung-107 study of ...
VisIC Technologies and AVL integrate GaN traction inverter into vehicle demonstrator, achieving over 99.8% efficiency and ...
Pathos AI launches multi-year collaborations to build an AI-driven dataset for Alzheimer’s and other neurological diseases.
xR detects gene rearrangements and specific splice variants in solid tumor tissue to support clinical management. A published study demonstrated that combining Tempus RNA and DNA testing increases ...
(NASDAQ: TEM, “Tempus”) today announced a multi-year agreement with Bristol Myers Squibb (NYSE: BMY, “BMS”), under which BMS ...
Substantially improved specificity of 2025 classification criteria for axial spondyloarthritis relative to 2009 criteria is largely driven by improved MRI methodology that clinicians must understand.
Pumitamig plus docetaxel demonstrated encouraging responses in squamous and non-squamous non-small cell lung cancer across PD-L1 expression levels with a confirmed objective response rate of ...
Tempus to build a de-identified dataset from hundreds of thousands of patients with neurological conditions; Pathos to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results